Back to Search Start Over

MiR-34a-HK1 signal axis retards bone marrow mesenchymal stem cell senescence via ameliorating glycolytic metabolism.

Authors :
Sun, Yanan
Zhang, Chang
Ma, Qianhui
Yu, Xiao
Gao, Xingyu
Zhang, Haiying
Shi, Yingai
Li, Yan
He, Xu
Source :
Stem Cell Research & Therapy; 7/30/2024, Vol. 15 Issue 1, p1-15, 15p
Publication Year :
2024

Abstract

Background: Mesenchymal stem cells (MSCs) are one of the most widely studied adult stem cells, while MSC replicative senescence occurs with serial expansion in vitro. We determined whether miR-34a can regulate MSC senescence by directly targeting glycolytic key enzymes to influence glycolysis. Methods: Detected the effects of miR-34a on MSC senescence and glycolytic metabolism through gene manipulation. Bioinformatics prediction and luciferase reporter assay were applied to confirm that HK1 is a direct target of miR-34a. The underlying regulatory mechanism of miR-34a targeting HK1 in MSC senescence was further explored by a cellular function recovery experiment. Results: In the current study, we revealed that miR-34a over-expression exacerbated senescence-associated characteristics and impaired glycolytic metabolism. Then we identified hexokinase1 (HK1) as a direct target gene of miR-34a. And HK1 replenishment reversed MSC senescence and reinforced glycolysis. In addition, miR-34a-mediated MSC senescence and lower glycolytic levels were evidently rescued following the co-treatment with HK1 over-expression. Conclusion: The miR-34a-HK1 signal axis can alleviate MSC senescence via enhancing glycolytic metabolism, which possibly provides a novel mechanism for MSC senescence and opens up new possibilities for delaying and suppressing the occurrence and development of aging and age-related diseases. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17576512
Volume :
15
Issue :
1
Database :
Complementary Index
Journal :
Stem Cell Research & Therapy
Publication Type :
Academic Journal
Accession number :
178777304
Full Text :
https://doi.org/10.1186/s13287-024-03857-3